This prospective study aims to detect early-stage lung cancer using low-dose computed tomography (LDCT) in Mexicans aged 50 or older who are current or former heavy smokers, non-smokers exposed to significant wood smoke, or diagnosed with COPD. Annual LDCT, spirometry, and serum biomarker tests will be conducted over 3 years, and a follow-up lasting up to 10 years.
This prospective cohort study aims to detect lung cancer in early stages using LDCT scans in Mexican individuals aged 50 years or older. Eligible participants comprise current smokers with a history of ≥ 20 pack-years, former smokers who have quit within the past 15 years, non-smokers exposed to wood smoke more than 100 hours/year, or patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD). Secondary objectives include assessing the 10-year mortality rate, the association of lung cancer with immunologic biomarkers, the demographic characterization of participants, the psychological impact of an LC screening program, the histological profiling of positive cases, lung function changes in at-risk individuals, and the clinical staging distribution at diagnosis. The study will conduct annual LDCT scans, lung function tests (spirometry), anxiety and depression assessments, and serum biomarkers tests over 3 years. Positive LDCT results will adhere to LUNG-RADS guidelines and be managed by a multidisciplinary team. Prevention strategies, including tobacco cessation treatments, will be provided. Follow-up will continue for 5 and 10 years or until an event of completion occurs (cancer diagnosis, end of follow-up, or death).
Study Type
OBSERVATIONAL
Enrollment
1,000
Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
Instituto Nacional de Cancerologia (INCan) Mexico
Mexico City, Tlalpan, Mexico
RECRUITINGLung cancer incidence in Mexican population
Assess the number of lung cancer detections after each round of screening.
Time frame: Annually over 3-year from inclusion
Lung cancer survival
Assess lung cancer mortality in participants included in the screening protocol and outside the protocol.
Time frame: 10-year follow-up or death from lung cancer
All-cause mortality
Asses all-cause mortality related to risk factors at the 3-years of LDCT screening and follow-up
Time frame: 10-year follow-up or death from lung cancer
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.